CDK4 is an important therapeutic target for cancer treatment, such that its inhibitors, including palbociclib, ponatinib and ribociclib [32–34], can block cell cycle progression, DNA damage response and immune modulation to suppress the cancer progression [35]. The gene discussed is CDK4; the disease is cancer.